IBEX 35
11.001,00 +83,50 (+0,76%) Euro Stoxx 50
4.988,83 +31,87 (+0,64%) Dólar/Euro
1,0767 -0,0007 (-0,06%) Petróleo Brent
83,15 -0,18 (-0,22%) Oro
2.323,20 -8,00 (-0,34%) Bitcoin EUR
59.323,45 -994,74 (-1,65%)
REGENXBIO Inc. (RGNX)
Después del cierre:
REGENXBIO Inc.
9804 Medical Center Drive
Rockville, MD 20850
United States
240 552 8181
https://www.regenxbio.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 344
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Kenneth T. Mills | President, CEO & Director | 1M | 720,99k | 1975 |
| Mr. Vittal K. Vasista | Executive VP & CFO | 666,5k | 573,3k | 1968 |
| Mr. Curran M. Simpson M.S. | Executive VP & COO | 698,6k | N/A | 1962 |
| Dr. Olivier Danos Ph.D. | Executive VP & Chief Scientific Officer | 778,85k | N/A | 1958 |
| Dr. Stephen Pakola M.D. | Executive VP & Chief Medical Officer | 674,05k | N/A | 1969 |
| Mr. Patrick J. Christmas II, J.D. | Executive VP & Chief Legal Officer | 1,11M | 1,29M | 1971 |
| Ms. Shiva G. Fritsch | Chief Communications & People Officer | N/A | N/A | N/A |
| Dr. Laura A. Coruzzi J.D., Ph.D. | Executive Vice President of Intellectual Property | N/A | N/A | 1954 |
| Dr. Ram Palanki Pharm.D. | Executive VP of Commercial Strategy & Operations | N/A | N/A | 1976 |
Descripción
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Gobierno corporativo
El ISS Governance QualityScore de REGENXBIO Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 3; Tablero: 8; Derechos de los accionistas: 8; Compensación: 8.
